You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Disease-Modifying Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Parkinson's Disease Trial (Lithium aspartate)

Not yet recruiting
  • Parkinson's Disease
  • Lithium aspartate
  • (no location specified)
Oct 27, 2023

Describe Switching FromFirst- or Second-line Disease Modifying

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Dec 12, 2022

    Antibody Response to COVID19 Vaccination in Multiple Sclerosis

    Completed
    • Multiple Sclerosis
    • Covid19
      • Livingston, New Jersey
        Saint Barnabas Medical Center
      Aug 16, 2022

      Post-COVID-19 Syndrome Trial in Geneva (Temelimab 54mg/kg, Placebo)

      Not yet recruiting
      • Post-COVID-19 Syndrome
      • Temelimab 54mg/kg
      • Placebo
      • Geneva, Switzerland
        Geneva University Hospital
      Aug 9, 2022

      Multiple Sclerosis Trial in Cambridge (Metformin and clemastine in combination, Placebo)

      Recruiting
      • Multiple Sclerosis
      • Metformin and clemastine in combination
      • Placebo
      • Cambridge, United Kingdom
        Addenbrooke's Hospital
      Jun 14, 2022

      Parkinson's Disease Trial in Houston (MSC+, MSC, Placebo)

      Active, not recruiting
      • Parkinson's Disease
      • MSC+placebo
      • +2 more
      • Houston, Texas
        The University of Texas Health Science Center at Houston
      Jan 26, 2022

      Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia Trial (combination product, drug, other)

      Not yet recruiting
      • Dyslipidemias
      • +4 more
      • Combination Therapy
      • +5 more
      • (no location specified)
      Aug 22, 2023

      Rheumatoid Arthritis Trial (GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg)

      Withdrawn
      • Rheumatoid Arthritis
      • (no location specified)
      May 11, 2022

      Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With

      Not yet recruiting
      • Multiple Sclerosis
      • Istanbul, Uskudar, Turkey
        Health Sciences University Istanbul Haydarpaşa Numune Training a
      Aug 25, 2021

      Rheumatoid Arthritis Trial in Pondicherry (Methotrexate, Leflunomide, Hydroxychloroquine)

      Terminated
      Has Results
      • Rheumatoid Arthritis
      • Pondicherry, India
        Department of Clinical Immunology , Jawaharlal Institute of Post
      Jul 25, 2021

      Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Germany, United States (Tetanus, diphtheria, and acellular

      Recruiting
      • Multiple Sclerosis
      • Multiple Sclerosis, Relapsing-Remitting
      • Tetanus, diphtheria, and acellular pertussis vaccine
      • +2 more
      • Palo Alto, California
      • +47 more
      Jun 24, 2022

      Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome Trial in United States (topiramate, Placebo)

      Completed
      • Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
      • Birmingham, Alabama
      • +19 more
      Mar 29, 2022

      Multiple Sclerosis Trial in Worldwide (Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon)

      Active, not recruiting
      Has Results
      • Multiple Sclerosis
      • Alemtuzumab GZ402673
      • +11 more
      • Wien, Austria
      • +20 more
      Jun 16, 2022

      Sickle Cell Disease Trial in United States (Mobile DOT)

      Completed
      • Sickle Cell Disease
      • Mobile DOT
      • Washington, District of Columbia
      • +3 more
      Mar 3, 2021

      Parkinson Disease Trial in Roma (Physical activity training)

      Recruiting
      • Parkinson Disease
      • Physical activity training
      • Roma, Italy
        Flavia Torlizzi
      Apr 4, 2023

      Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified

      Not yet recruiting
      • Coronary Artery Disease
      • Shockwave Medical Coronary IVL System
      • (no location specified)
      Mar 2, 2023

      Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

      Completed
      • Multiple Sclerosis
      • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
      • Prague, Czechia
        IMPULS Endowment Fund
      Mar 7, 2023

      Multiple Sclerosis Trial in Melsbroek

      Completed
      • Multiple Sclerosis
        • Melsbroek, Vlaams Brabant, Belgium
          Nationaal MS center
        Apr 17, 2023

        Lewy Body Disease, Healthy Aging Trial (transcranial direct current stimulation (tDCS))

        Not yet recruiting
        • Lewy Body Disease
        • Healthy Aging
        • transcranial direct current stimulation (tDCS)
        • (no location specified)
        Apr 26, 2023

        Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either

        Recruiting
        • Alpha-1 Antitrypsin Deficiency (AATD)
        • +2 more
        • Alvelestat (MPH966)
        • Placebo
        • Birmingham, Alabama
        • +8 more
        Aug 31, 2021

        Discontinuation of Disease Modifying Therapies in Multiple

        Completed
        • Multiple Sclerosis
          • Aurora, Colorado
          • +9 more
          Dec 15, 2022

          Kesimpta Pregnancy and Infant Safety Study Using Real World Data

          Not yet recruiting
          • Multiple Sclerosis
          • Multiple sclerosis disease modifying drug
          • (no location specified)
          Nov 27, 2023

          MDS Trial (Fasting-mimicking diet (FMD) and physiotherapy)

          Not yet recruiting
          • Myelodysplastic Syndromes
          • Fasting-mimicking diet (FMD) and physiotherapy
          • (no location specified)
          Jun 22, 2022

          Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab

          Completed
          • Multiple Sclerosis
            • East Hanover, New Jersey
              Novartis
            Jul 14, 2023

            Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs

            Completed
            • Arthritis, Rheumatoid
              • Tokyo, Japan
                Pfizer
              Nov 28, 2022